Core Insights - Fulcrum Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing small molecules for genetically defined rare diseases [3] - The company will participate in a fireside chat at the 46th Annual Goldman Sachs Global Healthcare Conference on June 11, 2025 [1] - Fulcrum's lead clinical program is pociredir, aimed at increasing fetal hemoglobin expression for treating sickle cell disease [3] Company Overview - Fulcrum Therapeutics specializes in small molecule development to address high unmet medical needs in rare diseases [3] - The company employs proprietary technology to identify drug targets that modulate gene expression [3] - More information about the company can be found on their website and social media platforms [3]